SCHEMBL5772886

SCHEMBL5772886

Cc1ccc(C)c(N2CCN(S(=O)(=O)c3cccc(CC(=O)O)c3)CC2)c1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.69
USP2 O75604 3/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
TSHR P16473 4/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
HTT P42858 2/20 0.55
CREBBP Q92793 1/20 0.55
POLB P06746 2/20 0.55
KDM4E B2RXH2 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NAMPT P43490 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.52
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748086 0.91 MAPT (0.58) LMNAUSP2L3MBTL1MAPTSMN1; SMN2
SCHEMBL5746076 0.90 LMNA (0.69) LMNAUSP2L3MBTL1TSHRMAPT
SCHEMBL5775668 0.85 MAPT (0.53) LMNAUSP2L3MBTL1TSHRMAPT
SCHEMBL5749068 0.84 MAPT (0.55) LMNAUSP2L3MBTL1TSHRMAPT
SCHEMBL5749033 0.83 HDAC3 (0.56) LMNAUSP2TSHRSMN1; SMN2KMT2A
SCHEMBL6357532 0.81 HTT (0.58) LMNASMN1; SMN2MEN1KMT2AHTT
SCHEMBL5799614 0.81 ALDH1A1 (0.65) LMNATSHRSMN1; SMN2MEN1KMT2A
SCHEMBL13804969 0.81 POLB (0.59) LMNAUSP2TSHRSMN1; SMN2KMT2A
SCHEMBL5747349 0.81 GAA (0.69) LMNAUSP2TSHRMAPTSMN1; SMN2
SCHEMBL5746151 0.79 L3MBTL1 (0.50) LMNAL3MBTL1TSHRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD LMNA 3289/4885USP2 2234/4885L3MBTL1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.